Synthesis of ABE tricyclic analogues of methyllycaconitine using a Wacker oxidation—aldol strategy to append the B ring to the AE fragment

David Barker,^a Margaret A. Brimble,^{*b} Malcolm McLeod,^{*a} G. Paul Savage^c and David J. Wong^a

- ^a School of Chemistry, F11 University of Sydney, Camperdown, NSW 2006, Australia
- ^b Department of Chemistry, University of Auckland, Private Bag 92019, Auckland, New Zealand. E-mail: m.brimble@auckland.ac.nz; Fax: +64 9 3737422
- ^c CSIRO Molecular Science, Bag 10, Clayton South, Vic. 3169, Australia

Received (in Cambridge, UK) 3rd January 2002, Accepted 14th February 2002 First published as an Advance Article on the web 27th February 2002

The synthesis of ABE tricyclic analogues 18 of the alkaloid methyllycaconitine 1 is described. The analogues contain the key pharmacophore reputed to be responsible for the biological activity of methyllycaconitine 1, namely, a homocholine motif formed from a tertiary *N*-ethylamine in a 3-azabicyclo[3.3.1]nonane ring system and a 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoate ester side chain. The 3-azabicyclo[3.3.1]nonane ring system 10 was assembled *via* a double Mannich reaction of ethyl 3-(but-3'-enyl)-2-oxocyclohexane-1-carboxylate 9 with ethylamine and formaldehyde. Attempts to append a B ring to this AE ring system *via* McMurray coupling of dialdehyde 5 were hampered by the inability to effect conversion of the C-9 ketone 10 to vinyl ether 6. Wittig methylenation of ketone 10 afforded diene 7, however, subsequent attempts to effect double hydroboration—oxidation of diene 7 failed to realise diol 11 *en route* to the key dialdehyde precursor 5 required for the McMurray coupling. Wacker oxidation of the homoallyl group of 10 afforded methyl ketone 12 which underwent intramolecular aldol condensation to form enone 13. After selective reduction of the ketone and methylation, the resultant methyl ethers 15 underwent reduction of the ester sidechain affording neopentyl substituted alcohols 16. Finally, the 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoate ester sidechain was appended by treatment of alcohols 16 with *N*-(trifluoroacetyl)anthranilic acid followed by fusion of the resultant anthranilates 17 with methylsuccinic anhydride.

Introduction

Methyllycaconitine 1 is the principle toxin in *Delphinium brownii*, a cattle-stock poison in Western Canada, and is also found in at least 30 *Delphinium* species as well as in *Consolida ambigua* and *Inaularoyaleana*. Both its toxicity and insecticidal activity have been attributed to its ability to act as a potent inhibitor of the nicotinic acetylcholine receptor (nAChR) binding in mammalian and insect neural membranes. At the α -7 subtype of nAChR, methyllycaconitine 1 is among the most potent, small molecule competitive antagonists yet reported.

Methyllycaconitine 1 is the 2-[2-(S)-methylsuccinimido]benzoate ester of the norditerpenoid alkaloid lycoctonine 2.⁶ Lycoctonine 2, however, exhibits 2000 times less affinity for rat neuronal $\alpha 7$ subtype nAChRs than its substituted anthranilate ester methyllycaconitine $1.^5$ The high toxicity of methyllycaconitine 1 to mammals prevents its use as an agrochemical, however, if the inhibitory action of methyllycaconitine 1 is localised in a small toxophoric section of the molecule, a subunit of methyllycaconitine 1 based on this section, may have the desired toxophoric properties yet be significantly lower in toxicity towards mammals. Therefore interest in synthesizing analogues of methyllycaconitine 1 as lead compounds for the development of new insecticides continues.

The N-substituted anthranilate ester moiety is considered an essential structural feature for insecticidal and pharmacological activity. It has also been proposed that at physiological pH the tertiary amine in the homocholine motif embedded in the AF rings of methyllycaconitine 1 is protonated and therefore mimics acetylcholine, and that the (S)-methylsuccinimido ring may help to maintain the correct geometry between the tertiary nitrogen atom of the F ring in the alkaloid and the carbonyl oxygen of the ester bond. We therefore herein report the synthesis of tricyclic analogues of methyllycaconitine 18 containing the key 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoate ester in which an additional six membered ring (a B ring) is appended to a 3-azabicyclo[3.3.1]nonane framework (the AE rings). It was envisaged that incorporation of the N-substituted anthranilate ester and the N-ethyl group embedded in the homocholine motif, into a conformationally restricted framework may enhance the biostability, selectivity and potency of simpler bicyclic AE analogues of methyllycaconitine 1 that had been prepared previously.

Methyllycaconitine 1 has not succumbed to total synthesis, however, a semi-synthesis of methyllycaconitine 1 from its parent alkaloid lycoctonine 2 has been reported by Blagbrough and co-workers 8 which established the absolute configuration of the methylsuccinimide moiety to be S. Alternative semi-syntheses of methyllycaconitine 1 from lycoctonine 2 used a 2-(N-succinimido)benzoic acid to append the anthranilate ester moiety to a neopentyl alcohol. 9

Simple E ring analogues of methyllycaconitine 1 containing the homocholine motif have been prepared by Bergmeier et al. 10 containing a piperidine ring substituted at C-3 with a 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoate ester. AE bicyclic analogues of methyllycaconitine 1 have been prepared by Blagbrough and co-workers 11 in which the 3-azabicyclo[3.3.1]-nonane framework was assembled via a double Mannich reaction using 2-oxocyclohexane-1-carboxylate, ethylamine and formaldehyde. The azabicyclo[3.3.1]nonane bicyclic skeleton was then extended from the ketone at C-5 by the addition of Grignard, Wittig and alkyllithium reagents. 12

To date the main attention for the synthesis of tricyclic analogues of methyllycaconitine 1 has been focused on assembly of AEF analogues. One approach by Kraus and Dneprovskaia ¹³ involved carrying out a similar Mannich reaction on a spirocyclic enone whereas Whiting and co-workers ¹⁴ formed the azabicyclic system *via* condensation of an ester with an amine formed by reduction of a nitrone that in turn had been formed by oxidative cleavage of an isoxazolidine. The work reported herein provides methodology for the synthesis of the first examples of tricyclic analogues of methyllycaconitine 1 that contain an ABE framework. The synthetic work reported herein was prompted by a report that an ABE tricyclic analogue of methyllycaconitine 1 was more potent than an AE bicyclic analogue, however, the synthesis and characterisation of the ABE tricyclic analogue was not described. ¹⁵

Results and discussion

Initial synthetic effort was directed towards the synthesis of ABE tricyclic analogue 3 which contains a dihydroxylated seven membered B ring (Scheme 1). Our synthetic strategy to prepare

Et-
$$N$$
 E B CO_2 Et O CO_2 Et R $CO_$

analogue 3 hinged on the use of a McMurray coupling to assemble diol 4 from dialdehyde 5. It was envisaged that the butyraldehyde side chain in dialdehyde 5 would be formed *via* hydroboration of an alkene and that the second aldehyde group could be generated *via* hydrolysis of enol ether 6. In turn enol ether 6 was available *via* Wittig olefination of ketone 10.

Homoallylation of β -keto ester **8** was performed efficiently using the method reported by Huckin and Weiler. ¹⁶ Thus β -keto

ester **8** was treated with NaH to generate the sodium enolate followed by the addition of butyllithium at 0 °C in dry THF to generate the dianion. Subsequent addition of 4-bromobut-1-ene and warming the reaction mixture to room temperature afforded the desired butenyl-substituted keto ester **9** in 83% yield (Scheme 2). The ¹H NMR spectrum of the product **9** was in agreement with the literature.¹⁷

Scheme 2 Reagents, conditions and yields: (i) NaH, THF (2.0 equiv.), 0 °C, 10 min, then BuLi (1.6 equiv.), 0 °C, 25 min, 4-bromobut-1-ene, 0 °C, 2 h then room temp., 20 h (83%) (ii) EtNH₂, H₂CO, EtOH, reflux, 24 h (41%) (iii) Ph₃P⁺CH₃Br⁻ (4.0 equiv.), BuLi (3.0 equiv.), THF, refux, 24 h (85%).

With butenyl-substituted keto ester 9 in hand, attention then turned to the formation of the azabicyclic ring system present in the AE rings of methyllycaconitine 1. Keto ester 9 was heated under reflux with one equivalent of ethylamine and two equivalents of formaldehyde in ethanol for 24 h to afford Mannich product 10 in 41% yield. The moderate yield obtained for this step is consistent with reports in the literature that state that double Mannich reactions using cyclohexanones that are substituted with only one carboxylate group at the α position such as keto ester 9, proceed in much lower yield than analogous reactions carried out using more highly activated cyclohexanones that are substituted with esters at both the α and α' positions. This is due to the low reactivity of the alternative α' carbon in β keto ester 9 (i.e. C-6) relative to the highly acidic α -position (C-2).

Elemental analysis of 10 was consistent with the required formula $C_{17}H_{27}NO_3$. In the ¹H NMR spectrum 7A-H characteristically resonated at $\delta_{\rm H}$ 2.86–2.98 further downfield than 7B-H due to the deshielding influence of the nearby nitrogen lone pair. This feature of the spectrum together with the long range W-coupling observed between 2A-H and 4A-H ($J_{2A,4A}$ 2.2 Hz) were consistent with formation of the 3-azabicyclo[3.3.1]-nonane ring system (Fig. 1). ¹⁹ The large upfield shift of 2B-H ($\delta_{\rm H}$ 2.86–2.98) and 4B-H ($\delta_{\rm H}$ 2.55) compared to their geminal protons 2A-H and 4A-H respectively, is attributed to the overlap of the nitrogen lone pair with the adjacent *trans*-coplanar C–H anti-bonding orbitals.

The proposed conversion of azabicyclo[3.3.1]nonane 10 to ABE analogue 4 required initial preparation of dialdehyde 5 proceeding by way of methyl vinyl ether 6. Unfortunately,




Fig. 1 Characteristic features in the ¹H NMR spectrum of 10.

attempts to effect Wittig olefination of ketone 10 with methoxymethyltriphenylphosphonium chloride using either butyllithium, LDA or NaH–DMSO as base were disappointing despite the successful use of these reagents to effect a similar conversion on a simpler keto ester which lacked a butenyl side chain at C-5.¹¹ Use of methoxymethyldiphenylphosphine oxide was also unsuccessful

Due to the inaccessibility of dialdehyde 5 from methyl vinyl ether 6, it was decided to alter the synthesis of 6 in light of our observation that the Wittig reaction of a keto ester analogous to 10 which lacked the butenyl group at C-5, proceeded in much higher yield using methyltriphenylphosphonium bromide rather than methoxymethyltriphenylphosphonium chloride. It was therefore envisaged that dialdehyde 5 could also be synthesised by the double oxidation of diol 11 which in turn could be synthesised by effecting a double hydroboration of diene 7. Treatment of keto ester 10 with methyltriphenylphosphonium bromide (4 equiv.) using butyllithium as base afforded the desired diene 7 in 85% yield after heating the reaction mixture under reflux for 24 h. With diene 7 in hand, attention then turned to its conversion to diol 11.

Treatment of diene 7 with excess dicyclohexylborane ²⁰ only effected hydroboration of the less hindered olefin in the butenyl side chain as evidenced by the disappearance of only the resonances due to the butenyl vinylic protons in the ¹H NMR spectrum of the crude product. Use of a large excess of borane–dimethyl sulfide for 24 h similarly did not result in hydroboration of the more hindered olefin at C-9 and neither did the use of borane generated *in situ* from sodium borohydride and boron trifluoride–diethyl ether and 9-borabicyclo[3.3.1]nonane.

The unsuccessful attempts to prepare dialdehyde 5 from diene 7 meant that efforts to synthesize the B ring of ABE tricyclic methyllycaconitine analogues derived from diol 4 using a pinacol coupling were abandoned. It was therefore decided to explore alternative avenues to produce tricyclic ABE analogues of methyllycaconitine.

In an alternative approach for the synthesis of ABE tricyclic analogues of methylycaconitine 1 it was envisaged that appendage of a B ring to the AE bicyclic system could be achieved by intramolecular ring-closure of a suitably appended nucleophile at C-5 of the azabicyclic system onto the carbonyl group at C-9. The nucleophile could be generated at this position by forming the enolate of methyl ketone 12 which in turn can be formed by Wacker oxidation of alkene 10 (Scheme 3).

Alkene 10 was treated with palladium(II) chloride (0.2 equivalents) and copper(I) chloride (1.2 equivalents) and the mixture stirred overnight whilst bubbling oxygen through the reaction vessel. After purification of the reaction mixture the desired product 12 was isolated in 39% yield after purification by flash chromatography. Use of DMF as solvent maximised the formation of methyl ketone 12 and minimised the competing double isomerization reaction.²¹ Copper(I) chloride was also used rather than copper(II) chloride in order to reduce competing chlorination of the carbonyl group²² and to increase the rate of the reaction.²³

With a reliable synthesis of methyl ketone 12 in hand, attention turned to the use of an intramolecular aldol cyclisation to convert 12 into enone 13. Treatment of methyl ketone 12 with potassium hexamethyldisilazanide, sodium hexamethyldisil-

Scheme 3 Reagents, conditions and yields: (i) PdCl₂, CuCl, O₂, 8:1 DMF–H₂O, room temp., 24 h (39%) (ii) KOH (4.0 equiv.), EtOH, room temp., 2 h (96%) (iii) NaBH₄, THF, H₂O (81%) (iv) NaH, THF, 1 h then MeI, 20 h (86%) (v) LiAlH₄, THF, 0 °C, 30 min (86%) (vi) N-(trifluoroacetyl)anthranilic acid, DMAP, DCC, MeCN, 40 °C, 24 h then NaBH₄, EtOH, room temp., 2 h (77%) (vii) 2-methylsuccinic anhydride, 125 °C, 36 h (50%).

azanide or lithium hexamethyldisilazanide only returned starting material as did use of potassium *tert*-butoxide in THF and the amino acids phenylalanine and proline. Finally success was realised when ketone 12 was treated with ethanolic potassium hydroxide ²⁴ for 2 h affording the desired enone 13 in 96% yield after work up and purification by flash chromatography.

The high resolution mass spectrum recorded for enone 13 exhibited a molecular ion at m/z 291.1827, corresponding to the molecular formula $\rm C_{17}H_{25}NO_3$ and consistent with loss of water during the intramolecular aldol condensation of methyl ketone 12. The 1H NMR spectrum exhibited a vinylic proton at δ_H 5.55 and the infrared spectrum exhibited two carbonyl absorbances due to the ester and α,β unsaturated ketone at 1727 cm⁻¹ and 1676 cm⁻¹, respectively. The ^{13}C NMR spectrum showed the lack of resonances due to C-4' at δ_C 29.7 and C-9 at δ_C 212.9 in methyl ketone 12. A new protonated vinylic carbon at δ_C 120.3 was assigned to C-5 and a quaternary vinylic carbon at δ_C 167.7 was assigned to C-6.

With the tricyclic framework in place it was then required to convert the ester in 13 into an alcohol in preparation for attachment of the *N*-(methylsuccinimido)anthranilate ester sidechain. Direct reduction of ester 13 with lithium aluminium hydride would also introduce a secondary alcohol at C-4. Thus, in order to prevent complication of the subsequent esterification of the C-7 alcohol it was decided to convert the C-4 ketone into a methoxy group, before reduction of the ester. The

ketone at C-4 was therefore selectively reduced with sodium borohydride to give alcohol 14 which then underwent methylation to give methyl ether 15. Finally reduction of the ethyl ester gave the desired primary alcohol 16.

The initial selective reduction of ketone 13 proceeded readily in 81% yield using sodium borohydride in THF affording alcohols 14 as an inseparable 2.3:1 mixture of diastereomers for which the stereochemistry was not assigned. The high resolution mass spectrum for the mixture of alcohols 14 exhibited a molecular ion at m/z 293.1993, consistent with the molecular formula C₁₇H₂₇NO₃. The infrared spectrum of the product showed an absorbance at 3354 cm⁻¹ indicating a hydroxy group whilst an absorbance at 1726 cm⁻¹ showed that the ethyl ester was still present. In the ¹H NMR spectrum a two proton multiplet at $\delta_{\rm H}$ 4.07–4.11 simplified to a single proton multiplet upon addition of D₂O indicating a hydroxy proton was now present. The vinylic proton, 5-H, which resonated as a singlet at $\delta_{\rm H}$ 5.55 in the starting material was observed as two doublets at $\delta_{\rm H}$ 5.22 ($J_{\rm 5.4}$ 2.2 Hz) and $\delta_{\rm H}$ 5.31 ($J_{\rm 5.4}$ 3.9 Hz) indicating the presence of two isomeric allylic alcohols. Integration of the two resonances showed the ratio of isomers to be 2.3:1, with the resonance at $\delta_{\rm H}$ 5.22 arising from the major isomer and that at $\delta_{\rm H}$ 5.31 from the minor isomer.

The 13 C NMR spectrum indicated that the C-4 carbonyl resonance present in the starting material **13** at $\delta_{\rm C}$ 198.7 had disappeared and had been replaced by two new resonances for C-4 at $\delta_{\rm C}$ 67.1 for the major isomer and at $\delta_{\rm C}$ 67.3 for the minor isomer. The vinylic carbon, C-5, resonated at $\delta_{\rm C}$ 120.9 for the major isomer and at $\delta_{\rm C}$ 119.6 for the minor isomer. All other carbon resonances were coincidental.

The next step in the synthesis involved the conversion of alcohols 14 to methyl ethers 15 and was achieved using sodium hydride and excess methyl iodide in THF. After purification by flash chromatography methyl ethers 15 were isolated in 86% yield. The 1H NMR spectrum exhibited two new singlets at $\delta_{\rm H}$ 3.16 and $\delta_{\rm H}$ 3.17, which had a combined integration for three protons, in a ratio of 2.3 : 1. The larger singlet at $\delta_{\rm H}$ 3.16 was assigned to the methoxy group of the major isomer whilst the singlet at $\delta_{\rm H}$ 3.17 was assigned to the minor isomer. The vinylic proton, 5-H resonated at $\delta_{\rm H}$ 5.15 for the major isomer and $\delta_{\rm H}$ 5.21 for the minor isomer. The $^{13}{\rm C}$ NMR spectrum exhibited distinct resonances for the methoxy group, C-4 and C-5.

Reduction of the ethyl esters 15 to neopentyl alcohols 16 was achieved using lithium aluminium hydride in THF for 2 hours at room temperature. After workup, purification by flash chromatography afforded alcohols 16 as an inseparable 2.3:1 mixture of diastereomers in 86% yield. The high resolution mass spectrum for alcohols 16 exhibited a molecular ion at m/z265.1974, consistent with the molecular formula C₁₆H₂₆NO₂. The infrared spectrum exhibited a broad absorbance at 3445 cm⁻¹ due to the hydroxy group and no carbonyl absorbances, confirming reduction of the ester had taken place. The ¹H NMR spectrum showed the absence of resonances from the ethyl ester, whilst two doublets at $\delta_{\rm H}$ 3.37 ($J_{\rm gem}$ 11.1 Hz) and $\delta_{\rm H}$ 3.44 ($J_{\rm gem}$ 11.1 Hz) were assigned to the C-7 hydroxymethyl protons. The ¹³C NMR spectrum showed the absence of resonances due to the ethyl ester and a new methylene resonance at δ_C 74.4 was assigned to the C-7 hydroxymethyl group. The spectrum exhibited individual resonances, for both diastereomers, for the methoxy group, C-4, C-5 and C-6 whilst all the other carbons were coincidental.

With the successful synthesis of tricyclic ABE analogues 16 in hand, it next remained to append the key *N*-(methylsuccinimido)anthranilate ester group. Addition of the 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoate ester to alcohols 16 in a single synthetic step *via* esterification using 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoic acid using methods reported by Kraus and Dneprovskaia ¹³ were unsuccessful. Whiting *et al.* ¹⁴ have also reported the inability to effect direct esterification of benzyl alcohol with 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoic

acid using DCC as a coupling agent and attributed this to complications arising from the presence of nucleophilic imide carbonyl groups which can react with the activated acid leading to the formation of 1,3-oxazines.

An alternative two step procedure for attaching the 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoate ester to alcohols **16** was more fruitful and consisted of conversion of alcohols **16** to anthranilates **17** followed by reaction with 2-methylsuccinic acid to afford the 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoates **18**. The most common method for conversion of alcohols to anthranilate esters involves reaction of the alcohol with isatoic anhydride and catalytic base ²⁵ at high temperature, however, this method only proceeds in low yields when using hindered alcohols. ^{8,11,14} We therefore developed ²⁶ a high yielding and operationally simple method for the conversion of hindered alcohols to anthranilate esters which was applied to the conversion of alcohols **16** to anthranilates **17** in the present work.

Treatment of alcohols **16** with *N*-(trifluoroacetyl)anthranilic acid²⁷ and 1,3-dicyclohexylcarbodiimide in acetonitrile using 4-dimethylaminopyridine as acylation catalyst afforded the *N*-(trifluoroacetyl)anthranilates which were then on work up treated directly with sodium borohydride to effect cleavage of the trifluoroacetyl group affording anthranilates **17** in 77% yield. Finally fusion of anthranilates **17** with 2-methylsuccinic anhydride effected conversion to 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoate esters **18** in 50% yield.

In summary the successful synthesis of esters 18 which are ABE tricyclic analogues of the alkaloid methyllycaconitine 1 has been achieved. The analogues contain the key pharmacophore reputed to be responsible for the biological activity of 1, namely: a homocholine motif formed from a tertiary N-ethylamine in a 3-azabicyclo[3.3.1]nonane ring system and a 2-(3-methyl-2,5-dioxopyrrolin-1-yl)benzoate ester side chain. The key steps in the synthesis involved the use of a double Mannich reaction to assemble the 3-azabicyclo[3.3.1]nonane AE ring system in combination with the use of a Wacker oxidation-aldol reaction to append a six membered B ring to the AE framework. Appendage of the 2-(3-methyl-2,5dioxopyrrolin-1-yl)benzoate ester was effected by treatment of alcohols 16 with N-(trifluoroacetyl)anthranilic acid followed by fusion of the resultant anthranilates with 2-methylsuccinic anhydride.

Experimental

Mps were determined on a Koffler hot-stage apparatus and are uncorrected. IR spectra were recorded using a Perkin-Elmer 1600 Fourier Transform IR spectrophotometer as thin films between sodium chloride plates. Absorption spectra are expressed in wavenumbers (cm⁻¹) with the following abbreviations: s = strong, m = medium, w = weak and br = broad. ¹H NMR spectra were recorded on a Bruker AC 200 (200 MHz) or a Bruker DRX 400 (400 MHz) spectrometer at ambient temperature. All J-values are given in Hz. Chemical shifts are expressed in parts per million downfield shift from tetramethylsilane as an internal standard, and reported as position ($\delta_{\rm H}$), relative integral, multiplicity (s = singlet, br s = broad singlet, d = doublet, dd = double doublet, ddd = double doublet, t = triplet, q = quartet, m = multiplet) and assignment. ¹³C NMR spectra were recorded on a Bruker AC 200 (50.3 MHz) or a Bruker DRX 400 (100.5 MHz) spectrometer at ambient temperature with complete proton decoupling. Chemical shifts are expressed in parts per million downfield shift from tetramethylsilane as an internal standard and reported as position $(\delta_{\rm C})$, multiplicity (aided by DEPT 135, DEPT 90, COSY and HETCOR experiments) and assignment. When NMR data are reported for isomeric mixtures, resonances for the minor isomer are denoted by an asterisk (*). Low resolution mass spectra were recorded on a VG70-250S, a VG70-SD or a AEI model MS902 double focusing magnetic sector mass spectrometer operating with an ionisation potential of 70 eV. High resolution mass spectra were recorded at nominal resolution of 5000 to 10 000 as appropriate. Major fragments are given as percentages relative to the base peak and assigned where possible. Ionisation methods employed were either electron impact or chemical ionisation with ammonia or methane as reagent gas (CI). Low resolution chemical ionisation mass spectra were also recorded on a Hewlett Packard 5989A mass spectrometer using ammonia as reagent gas with the sample dissolved in methanol. Elemental analyses were carried out by the Microanalytical Unit at the Research School of Chemistry, Australian National University, Canberra. Flash chromatography was performed using Merck Kieselgel 60 (230-400 mesh) with the indicated solvents. Thin layer chromatography (tlc) was performed using 0.2 mm thick precoated silica gel plates (Merck Kieselgel 60 F₂₅₄ or Riedel-de Haen Kieselgel S F254). Compounds were visualised by ultraviolet fluorescence or by staining with iodine or vanillin in methanolic sulfuric acid.

Ethyl 3-(but-3'-enyl)-2-oxocyclohexane-1-carboxylate 9

A solution of ethyl 2-oxocyclohexane-1-carboxylate 8 (5.58 g, 32.8 mmol) in dry THF (10 mL) was added dropwise to a suspension of sodium hydride (1.56 g, 65.0 mmol) in dry THF (100 mL) at 0 °C. n-BuLi (21.0 mL, 52.5 mmol, 2.5 M solution in hexane) was added dropwise to the reaction mixture which was stirred for 25 min followed by the addition of a solution of 4-bromobut-1-ene (4.43 g, 32.8 mmol) in dry THF (5 mL). Stirring was continued at 0 °C for 2 h then at room temperature for 20 h. The reaction mixture was quenched with distilled water (20 mL) and the solvent removed at reduced pressure to afford an orange oil. Saturated ammonium chloride solution (150 mL) was added to the resulting crude oil and the organic material extracted with ethyl acetate (3 × 100 mL). The combined organic extracts were dried over anhydrous sodium sulfate and the solvent was removed at reduced pressure to afford a dark orange oil. Purification by flash chromatography (19: 1 hexane-ethyl acetate) afforded the title compound 9 (6.10 g, 83%) as a yellow oil for which the ¹H NMR data were in agreement with the literature.17

Ethyl $(1R^*,5S^*)$ -5-(but-3'-enyl)-3-ethyl-9-oxo-3-azabicyclo-[3.3.1]nonane-1-carboxylate 10

A mixture of ethyl 3-(but-3'-enyl)-2-oxocyclohexane-1-carboxylate 9 (1.01 g, 4.50 mmol), ethylamine (674 mg, 4.48 mmol, 30% aq. v/v) and formaldehyde (750 mg, 8.99 mmol, 36% aq. v/v) in ethanol (60 mL) was heated under reflux for 24 h. After removal of the solvent at reduced pressure, the dark yellow oil was dissolved in ether (70 mL) and extracted with 2 M hydrochloric acid (3×80 mL). The aqueous extract was made basic with 10% sodium hydroxide solution (250 mL) whilst cooling with ice then extracted with ether (3 × 150 mL) and dried over anhydrous sodium sulfate. The solvent was removed at reduced pressure and the resultant yellow oil purified by flash chromatography (9: 1 hexane-ethyl acetate) to afford the title compound 10 (546 mg, 41%) as a pale yellow oil (Found: C, 69.4; H, 9.2; N, 4.8. $C_{17}H_{27}NO_3$ requires C, 69.6; H, 9.3; N, 4.8%); v_{max} (NaCl)/cm⁻¹ 1736 (C=O, ester) and 1718 (C=O, ketone), 1640 (C=C); $\delta_{\rm H}$ (400 MHz, CDCl₃) 1.09 (3H, t, J 7.2, NCH₂CH₃), 1.28 (3H, t, J 7.2, OCH₂CH₃), 1.41–2.22 (6H, m, 6-CH₂, 7B-H, 8B-H, 1'-CH₂), 2.26-2.29 (1H, m, 2'B-H), 2.39 (2H, q, J 7.2, NCH₂CH₃), 2.48-2.56 (2H, m, 8A-H, 2'A-H), 2.55 (1H, dd, J_{4B,2B} 1.7, J_{gem} 11.0, 4B-H), 2.86–2.98 (2H, m, 2B-H, 7A-H), 3.05 (1H, dd, $J_{4A,2A}$ 2.2, J_{gem} 11.0, 4A-H), 3.18 (1H, dd, $J_{2A,4A}$ 2.2, J_{gem} 11.3, 2A-H), 4.20 (2H, q, J 7.2, OC H_2 CH₃), 4.92 (1H, dd, J_{gem}^{om} 1.4, $J_{4'B,3'}$ 10.1, 4'B-H), 5.01 (1H, dd, J_{gem} 1.4, $J_{4'A,3'}$ 17.1, 4'A-H), 5.74–5.85 (1H, m, 3'-H); $\delta_{\rm C}$ (100 MHz, CDCl₃) 13.3 (CH₃, NCH₂CH₃), 14.8 (CH₃, OCH₂CH₃), 21.2 (CH₂, C-7), 28.4 (CH₂, C-1'), 34.7 (CH₂, C-6), 37.7 (CH₂, C-8), 39.8 (CH₂, C-2'), 49.8 (quat., C-5), 51.2 (CH₂, NCH₂CH₃), 59.7 (quat., C-1), 61.7 (CH₂, OCH₂CH₃), 62.5 (CH₂, C-4), 65.4 (CH₂, C-2), 114.9 (CH₂, C-4'), 139.6 (CH, C-3'), 172.1 (quat., OC=O), 213.7 (quat., C-9); m/z (EI) 293 (M⁺, 4), 278 (M - CH₃, 5), 252 (100), 238 (M - C₄H₇, 6). Found M⁺, 293.1979. C₁₇H₂₇NO₃ requires M^+ , 293.1991.

Ethyl (1*S**,5*S**)-5-(but-3'-enyl)-3-ethyl-9-methylidene-3-azabicyclo[3.3.1]nonane-1-carboxylate 7

n-BuLi (3.0 mL, 5.13 mmol, 1.7 M solution in hexane) was added dropwise to a suspension of methyltriphenylphosphonium bromide (2.44 g, 6.83 mmol) in dry THF (40 mL) at -78°C. The reaction mixture was stirred at 0 °C for 10 min then cooled to -78 °C followed by the dropwise addition of a soluethyl $(1R^*,5S^*)$ -5-(but-3'-enyl)-3-ethyl-9-oxo-3tion of azabicyclo[3.3.1]nonane-1-carboxylate 10 (500 mg, 1.70 mmol) in dry THF (10 mL). The reaction mixture was allowed to warm to room temperature then heated under reflux for 24 h. The reaction was quenched with distilled water (5 mL) and the solvent removed at reduced pressure. The residue was dissolved in dry ether (40 mL) and extracted with 2 M hydrochloric acid $(3 \times 80 \text{ mL})$. The aqueous extract was made basic with 10% sodium hydroxide solution then extracted with ether (3 × 100 mL) and dried over anhydrous sodium sulfate. The solvent was removed at reduced pressure and the resultant dark yellow oil purified by flash chromatography (19:1 hexane-ethyl acetate) to afford the title compound 7 (420 mg, 85%) as a pale yellow oil. $v_{\text{max}}(\text{NaCl})/\text{cm}^{-1}$ 1727 (C=O, ester), 1640 (C=C); δ_{H} (400 MHz, CDCl₃) 1.08 (3H, t, J 7.1, NCH₂CH₃), 1.32 (3H, t, J 7.1, OCH₂CH₃), 1.40–1.53 (5H, m, 7B-H, 6-CH₂ and 8B-H), 1.88–1.98 (3H, m, 1'-CH₂ and 2'-CH₂), 2.07–2.26 (2H, m, 4B-H and 8A-H), 2.31 (2H, q, J 7.1, NCH₂CH₃) 2.59 (1H, dd, $J_{2B,4B}$ 2.1, J_{gem} 10.7, 2B-H), 2.85–2.91 (1H, m, 7A-H), 2.93 (1H, d, J_{gem} 11.2, 4A-H), 3.05 (1H, d, J_{gem} 10.7, 2A-H), 4.22 (2H, q, J 7.1, OC H_2 CH₃), 4.61 (1H, br s, 10A-H), 4.75 (1H, br s, 10B-H), 4.98 (1H, dd, $J_{4'B,3'}$ 10.1, J_{gem} 1.7, 4'B-H), 5.06 (1H, dd, $J_{4'\text{A},3'}$ 17.1, J_{gem} 1.7, 4'A-H), 5.80–5.90 (1H, m, 3'-H); δ_{C} (100 MHz, CDCl₃) 13.2 (CH₃, NCH₂CH₃), 14.9 (CH₃, OCH₂CH₃), 21.7 (CH₂, C-7), 28.4 (CH₂, C-1'), 36.7 (CH₂, C-6), 38.4 (CH₂, C-8), 38.7 (CH₂, C-2'), 40.7 (quat., C-5), 52.6 (quat., C-1), 52.8 (CH₂, NCH₂CH₃), 61.1 (CH₂, OCH₂CH₃), 62.9 (CH₂, C-4), 65.3 (CH₂, C-2), 103.7 (CH₂, C-10), 114.8 (CH₂, C-4'), 140.0 (CH, C-3'), 155.4 (quat., C-9) and 175.5 (quat., OC=O); m/z (EI) 291 (M⁺, 5), 276 (M - CH₃, 9), 262 (M - C_2H_5 , 10), 218 (M - $C_2H_5CO_2$, 19) and 58 (100). Found M^+ , 291.2217. $C_{18}H_{29}NO_2$ requires M^+ , 291.2198.

Ethyl $(1R^*,5S^*)$ -3-ethyl-9-oxo-5-(3'-oxobutyl)-3-azabicyclo-[3.3.1]nonane-1-carboxylate 12

A mixture of copper(I) chloride (445 mg, 4.50 mmol) and palladium(II) chloride (133 mg, 0.750 mmol) in DMF (10 mL) and water (2 mL) was stirred vigorously until the initially brownish solution became green (approximately 2 h). A solution of ethyl $(1R^*,5S^*)$ -5-(but-3'-enyl)-3-ethyl-9-oxo-3-azabicyclo[3.3.1]nonane-1-carboxylate 10 (1.10 g, 3.75 mmol) in DMF (5 mL) was then added and oxygen was bubbled through the mixture with stirring for 18 h. After this time water (100 mL) was added and the mixture extracted with ethyl acetate (5 × 100 mL). The combined organic extracts were washed with brine (3 × 100 mL) then dried (MgSO₄) and the solvent removed in vacuo to leave the crude product. Purification by flash chromatography (4:1 hexane-ethyl acetate) afforded the title compound 12 (449 mg, 39%) as an orange oil. $v_{\text{max}}(\text{NaCl})/\text{cm}^{-1}$ 1732 (C=O, ester) and 1715 (C=O, ketones); $\delta_{\rm H}$ (200 MHz, CDCl3) 1.04 (3H, t, J 7.1, NCH₂CH₃), 1.23 (3H, t, J 7.1, OCH₂CH₃), 1.37–1.82 (5H, m, 1'-CH₂, 6-CH₂ and 7B-H), 1.94–2.06 (1H, m, 8B-H), 2.09 (3H, s, COCH₃), 2.12-2.27 (2H, m, 2'-CH₂), 2.35 (2H, q, J 7.1, NCH₂CH₃), 2.40-2.55 (2H, m, 4B-H and 8A-H), 2.75-2.90 (2H, m, 2B-H and 7A-H), 2.94 (1H, dd, $J_{4A,2A}$ 2.1, J_{gem} , 11.3, 4A-H), 3.21 (1H, dd, $J_{2A,4A}$ 2.1, J_{gem} , 11.3, 2A-H) and

928

4.15 (2H, q, J 7.1, OC H_2 CH₃); δ_C (50 MHz, CDCl₃) 12.5 (CH₃, NCH₂CH₃), 14.0 (CH₃, OCH₂CH₃), 20.2 (CH₂, C-7), 28.4 (CH₂, C-1'), 29.7 (CH₃, C-4'), 36.7 (CH₂, C-6), 38.3 (CH₂, C-8), 39.4 (CH₂, C-2'), 48.7 (quat., C-5), 51.0 (CH₂, NCH₂CH₃), 58.8 (quat., C-1), 61.0 (CH₂, OCH₂CH₃), 61.6 (CH₂, C-4), 64.7 (CH₂, C-2), 171.1 (quat., OC=O), 208.5 (quat., C-3') and 212.9 (quat., C-9); m/z (EI) 309 (M⁺, 23%), 266 (M - CH₃CO, 21), 252 (M - C₃H₅O, 98), 238 (M - C₄H₇O, 13) and 43 (CH₃CO, 100). Found M⁺, 309.1958. C₁₇H₂₇NO₄ requires M^+ , 309.1940.

Ethyl $(1R^*,7S^*)$ -9-ethyl-4-oxo-9-azatricyclo $[5.3.3.0^{1.6}]$ tridec-5-ene-7-carboxylate 13

To a solution of potassium hydroxide (0.524 g, 9.33 mmol) in ethanol (25 mL) was added a solution of ethyl $(1R^*,5S^*)$ -3ethyl-9-oxo-5-(3'-oxobutyl)-3-azabicyclo[3.3.1]nonane-1-carboxylate 12 (0.723 g, 2.33 mmol) in ethanol (25 mL) and the mixture stirred for 1.5 h at room temperature. After this time brine (20 mL) was added and the solution diluted with water (100 mL). The aqueous solution was extracted with diethyl ether (3 × 50 mL), the combined organic layers washed with brine (50 mL) then dried (MgSO₄) and concentrated in vacuo to give the crude product. Further purification by flash chromatography (7: 3 hexane-ethyl acetate) afforded the title compound 13 (0.657 g, 96%) as a clear oil. $v_{\text{max}}(\text{NaCl})/\text{cm}^{-1}$ 2924 (C-H), 1727 (C=O, ester), 1676 (C=C-C=O), 1617 (C=C), 1457 and 1251; $\delta_{\rm H}$ (200 MHz, CDCl₃) 0.98 (3H, t, J 7.2, NCH₂CH₃), 1.18 (3H, t, J 7.1, OCH₂CH₃), 1.41–1.49 (1H, m, 12B-H), 1.60-1.95 (5H, m, 2-CH₂, 11-CH₂ and 13B-H), 2.00-2.35 (6H, m, 3-CH₂, 10B-H, 13A-H and NCH₂CH₃), 2.55 (1H, dd, $J_{8B,10B}$ 1.9, J_{gem} , 11.0, 8B-H), 2.81 (1H, dd, $J_{10A,8A}$ 1.1, J_{gem} , 11.8, 10A-H), 2.82–2.97 (1H, m, 12A-H), 3.00 (1H, dd, $J_{8A,10A}$ 1.1, J_{gem} , 11.0, 8A-H), 4.09 (2H, q, J 7.1, OC H_2 CH₃) and 5.55 (1H, br s, 5-H); δ_C (50 MHz, CDCl₃) 12.2 (CH₃, NCH₂CH₃), 13.9 (CH₃, OCH₂CH₃), 20.3 (CH₂, C-12), 32.8 (CH₂, C-2), 33.1 (CH₂, C-11), 36.5 (CH₂, C-3), 37.3 (quat., C-1), 38.1 (CH₂, C-13), 51.3 (CH₂, NCH₂CH₃), 51.8 (quat., C-7), 60.8 (CH₂, OCH₂CH₃), 61.1 (CH₂, C-10), 66.0 (CH₂, C-8), 120.3 (CH, C-5), 167.7 (quat., C-6), 172.4 (quat., OC=O) and 198.7 (quat., C-4); m/z (EI) 291 (M⁺, 65%), 276 (M - CH₃, 60), 262 (M - CH_2CH_3 , 61), 218 (M - $CO_2C_2H_5$, 44) and 58 (100). Found M^+ , 291.1827. $C_{17}H_{25}NO_3$ requires M^+ , 291.1834.

Ethyl (1R*,7S*)-9-ethyl-4-hydroxy-9-azatricyclo[5.3.3.0^{1,6}]-tridec-5-ene-7-carboxylate 14

To a solution of sodium borohydride (86 mg, 2.27 mmol) in THF (3 mL) and water (7 mL) was added a solution of ethyl $(1R^*,7S^*)$ -9-ethyl-4-oxo-9-azatricyclo[5.3.3.0^{1,6}]tridec-5-ene-7carboxylate 13 (0.657 g, 2.25 mmol) in THF (4 mL) and the mixture stirred for 8 h. After this time the reaction was quenched by the addition of water (20 mL) and the volatiles were removed in vacuo. The remaining aqueous solution was extracted with ethyl acetate (3×30 mL), the combined organic layers washed with brine (50 mL) then dried (Na₂SO₄) and concentrated in vacuo. The crude product was purified by flash chromatography (7: 3 hexane-ethyl acetate) to give the title compound 14 (0.535 g, 81%) as a clear oil and as a 2.3:1 inseparable mixture of isomers. $v_{\text{max}}(\text{NaCl})/\text{cm}^{-1}$ 3354 (O-H), 2931 (C-H), 1726 (C=O, ester), 1661 (C=C), 1451 and 1253; $\delta_{\rm H}$ (200 MHz, CDCl₃) 1.02 (3H, t, J 7.2, NCH₂CH₃), 1.26 (3H, t, J 7.1, OCH₂CH₃), 1.38-1.59 (5H, m, 2-CH₂, 11B-H, 12B-H and 13B-H), 1.64-1.96 (4H, m, 3-CH₂, 11A-H and 13A-H), 2.13 (1H, dd, $J_{10B,8B}$ 2.0, J_{gem} , 10.3, 10B-H), 2.24 (2H, q, J 7.2, NC H_2 CH₃), 2.51 (1H, dd, $J_{8B,10B}$ 2.0, J_{gem} , 10.8, 8B-H), 2.74 (1H, d, J_{gem} , 10.3, 10A-H), 2.79–2.92 (1H, m, 12A-H), 2.99 (1H, d, J_{gem}, 10.8, 8A-H), 4.07–4.11 (2H, m, 4-H and OH), 4.16 (2H, q, J 7.1, OC H_2 CH₃), 5.22 (0.7H, d, $J_{5,4}$ 2.2, 5-H) and 5.31* (0.3H, d, $J_{5,4}$ 3.9, 5-H); $\delta_{\rm C}$ (50 MHz, CDCl₃) 12.4 (CH₃, NCH₂CH₃), 14.1 (CH₃, OCH₂CH₃), 20.9 (CH₂, C-12), 28.3 (CH₂, C-2), 32.4 (CH₂, C-11), 34.2 (CH₂, C-3), 36.2 (quat., C-1), 38.8 (CH₂, C-13), 38.9 (quat., C-7), 51.8 (CH₂, NCH₂CH₃), 60.5 (CH₂, OCH₂CH₃), 61.9 (CH₂, C-10), 66.9 (CH₂, C-8), 67.1 (CH, C-4), 67.3* (CH, C-4), 119.6* (CH, C-5), 120.9 (CH, C-5), 145.2 (quat., C-6) and 179.6 (quat., OC=O); m/z (EI) 293 (M⁺, 40%), 278 (M - CH₃, 78), 264 (M - CH₂CH₃, 14), 220 (M - COOC₂H₅, 42) and 42 (100). Found M⁺, 293.1993. C₁₇H₂₇NO₃ requires M⁺, 293.1991.

Ethyl $(1R^*,7S^*)$ -9-ethyl-4-methoxy-9-azatricyclo[5.3.3.0^{1,6}]-tridec-5-ene-7-carboxylate 15

To a suspension of sodium hydride (219 mg, 60% in oil, 5.48 mmol) in dry THF (20 mL) at 0 °C was added a solution of ethyl (1R*,7S*)-9-ethyl-4-hydroxy-9-azatricyclo[5.3.3.0^{1,6}]tridec-5-ene-7-carboxylate 14 (535 mg, 1.82 mmol) in dry THF (5 mL). The mixture was then stirred for 1 h after which time iodomethane (776 mg, 0.34 mL, 5.47 mmol) was added and the mixture stirred at room temperature for 20 h. The reaction was quenched by the careful addition of sat. ammonium chloride solution (20 mL). The volatile solvents were removed in vacuo and the remaining aqueous mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 \times 30 mL). The combined organic layers were washed with brine (50 mL) then dried (MgSO₄) and concentrated in vacuo to give the crude product which was purified by flash chromatography (7:3 hexane-ethyl acetate) to give the title compound 15 (484 mg, 86%) as a clear oil and as a 2.3:1 inseparable mixture of isomers. $v_{\text{max}}(\text{NaCl})/\text{cm}^{-1}$ 2932 (C–H), 1727 (C=O, ester), 1661 (C=C), 1453 and 1252; $\delta_{\rm H}$ (200 MHz, CDCl₃) 0.89 (3H, t, J 7.1, NCH₂CH₃), 1.12 (3H, t, J 7.0, OCH₂CH₃), 1.27–1.48 (5H, m, 2-CH₂, 11B-H, 12B-H and 13B-H), 1.56–1.88 (4H, m, 3-CH₂, 11A-H and 13A-H), 2.09 (2H, q, J7.1, NCH₂CH₃), 2.28 (1H, d, J_{gem} , 10.5, 10B-H), 2.43 (1H, d, J_{gem} , 10.8, 8B-H), 2.60 (1H, d, J_{gem}, 10.5, 10A-H), 2.63–2.79 (1H, m, 12A-H), 2.84 (1H, d, J_{gem}, 10.8, 8A-H), 3.16 (2.1H, s, OCH₃), 3.17* (0.9H, s, OCH₃), 3.54–3.58 (1H, m, 4-H), 4.01 (2H, q, J 7.0, OCH₂CH₃), 5.15 (0.7H, br s, 5-H) and 5.21* (0.3H, d, $J_{5,4}$ 3.6, 5-H); $\delta_{\rm C}$ (50 MHz, CDCl₃) 12.2 (CH₃, NCH₂CH₃), 13.9 (CH₃, OCH₂CH₃), 20.7 (CH₂, C-12), 23.9 (CH₂, C-2), 32.1 (CH₂, C-11), 35.1 (quat., C-1), 35.6 (CH₂, C-3), 38.7 (CH₂, C-13), 39.0 (quat., C-7), 51.6 (CH₂, NCH₂CH₃), 55.2 (CH₃, OCH₃), 55.6* (CH₃, OCH₃), 60.0 (CH₂, OCH₂CH₃), 61.8 (CH₂, C-10), 66.7 (CH₂, C-8), 73.9 and 75.4* (CH, C-4), 117.0* (CH, C-5), 117.9 (CH, C-5), 145.1 (quat., C-6) and 173.7 (quat., OC=O); m/z (EI) 307 (M⁺, 29%), 292 (M - CH₃, 44), 278 (M - CH₂CH₃, 22), 276 (M - OCH₃, 34), 234 (M - COOC₂H₅, 42) and 29 (CH₃CH₂, 100). Found M^+ , 307.2143. $C_{18}H_{29}NO_3$ requires M^+ , 307.2147.

$(1R^*,7S^*)$ -(9-Ethyl-4-methoxy-9-azatricyclo $[5.3.3.0^{1,6}]$ tridec-5-en-7-yl)methanol 16

To a slurry of lithium aluminium hydride (109 mg, 2.87 mmol) in dry THF (20 mL) at 0 °C, was slowly added a solution of ethyl $(1R^*,7S^*)$ -9-ethyl-4-methoxy-9-azatricyclo[5.3.3.0^{1,6}]tridec-5-ene-7-carboxylate 15 (442 mg, 1.44 mmol) in dry THF (20 mL) and the mixture stirred under an atmosphere of nitrogen for 30 min. The reaction was quenched by the slow addition of water (30 mL) and the volatiles removed in vacuo. The remaining aqueous mixture was extracted with ethyl acetate $(3 \times 20 \text{ mL})$ and the combined organic layers washed with brine (40 mL) then dried (Na₂SO₄) and concentrated in vacuo to give the crude product. Further purification by flash chromatography (1: 1 hexane-ethyl acetate) afforded the title compound 16 (329 mg, 86%) as a clear oil and as a 2.3: 1 inseparable mixture of isomers. $v_{\text{max}}(\text{NaCl})/\text{cm}^{-1}$ 3445 (O–H), 2929 (C–H), 1654 (C=C), 1452 and 1084; $\delta_{\rm H}$ (200 MHz, CDCl₃) 0.92 (3H, t, J 7.1, NCH₂CH₃), 1.28-1.64 (7H, m, 2-CH₂, 11-CH₂, 12B-H and 13-CH₂), 1.70-1.82 (3H, m, 3-CH₂, 10B-H), 2.11 (2H, q, J7.2, NC H_2 CH₃), 2.64 (1H, d, J_{gem} , 10.4, 8B-H), 2.71–2.82 (2H, m, 10A-H and 12A-H), 2.89 (1H, d, J_{gem}, 10.4, 8A-H), 3.11 (1H, brs, OH), 3.22 (2.1H, s, OCH₃), 3.24* (0.9H, s, OCH₃), 3.37 (1H, d, J_{gem} 11.1, $CH_{A}H_{B}OH$), 3.44 (1H, d, J_{gem} , 11.1, $CH_{A}H_{B}OH$), 3.57–3.70 (1H, m, 4-H), 5.20 (0.7H, d, $J_{5,4}$ 1.5, 5-H) and 5.28* (0.3H, d, $J_{5,4}$ 3.8, 5-H); δ_{C} (50 MHz, CDCl₃) 12.5 (CH₃, NCH₂CH₃), 20.7 (CH₂, C-12), 23.9 (CH₂, C-2), 31.5 (CH₂, C-11), 35.6 (quat., C-1), 36.2 (CH₂, C-3), 39.0 (quat., C-7), 41.3 (CH₂, C-13), 51.8 (CH₂, NCH₂CH₃), 55.3 (CH₃, OCH₃), 55.4* (CH₃, OCH₃), 62.1 (CH₂, C-10), 67.9 (CH₂, C-8), 74.4 (CH₂, OCH₂), 75.9 (CH, C-4), 76.3* (CH, C-4), 114.5* (CH, C-5), 115.7 (CH, C-5), 147.8 (quat., C-6) and 149.3* (quat., C-6); m/z (EI) 265 (M⁺, 1%), 250 (M - CH₃, 9), 234 (M - OCH₃, 10) and 72 (100). Found M⁺, 265.1974. $C_{16}H_{26}NO_2$ requires M^+ , 265.1964.

$(1'R^*,7'S^*)$ -(9-Ethyl-4-methoxy-9-azatricyclo[5.3.3.0^{1,6}]tridec-5-en-7-yl)methyl 2-aminobenzoate 17

To a mixture of alcohol 16 (70 mg, 0.264 mmol), N-(trifluoroacetyl)anthranilic acid 26,27 (246 mg, 1.06 mmol) and 4-(dimethylamino)pyridine (32 mg, 0.262 mmol) in acetonitrile (5 mL) was added 1,3-dicyclohexylcarbodiimide (217 mg, 1.05 mmol) and the mixture stirred, under an atmosphere of nitrogen, at 40 °C for 24 h. After this time the mixture was cooled, filtered and the filtrate evaporated to dryness. The crude mixture was then dissolved in dichloromethane (20 mL), washed with aq. sodium bicarbonate (20 mL) and brine (20 mL) then dried (MgSO₄) and concentrated in vacuo to leave the crude N-(trifluoroacetyl)anthranilate ester. This residue was suspended in absolute ethanol (10 mL), sodium borohydride (50 mg, 1.32 mmol) added, and the mixture stirred for 2 h. The reaction was quenched by the addition of water and the volatile solvent removed in vacuo. The remaining aqueous solution was extracted with ethyl acetate (2 × 30 mL) and the combined organic layers washed with brine (50 mL) then dried (MgSO₄) and concentrated in vacuo to leave the crude product, which was purified by flash chromatography using 7:3 hexane-ethyl acetate as eluent to afford the title compound 17 (78 mg, 77%) as a yellow oil and as a 2.3:1 inseparable mixture of isomers. $v_{\text{max}}(\text{NaCl})/\text{cm}^{-1}$ 3474 and 3370 (N-H), 2929 (C-H), 1689 (C= O), 1617, 1589, 1453, 1244 and 1099; $\delta_{\rm H}$ (200 MHz, CDCl₃) 1.04 (3H, t, J 7.2, NCH₂CH₃), 1.28-1.69 (8H, m, 2'-CH₂, 3'-CH₂, 11'-CH₂, 12'B-H and 13'B-H), 1.81 (1H, d, J_{eem} 11.2, 10'B-H), 2.00 (2H, q, J 7.2, NCH₂CH₃), 2.10-2.28 (2H, m, 10'A-H and 13'A-H), 2.80 (1H, d, J_{gem} , 10.4, 8'B-H), 2.84–3.04(1H, m, 12'A-H), 3.06 (1H, d, J_{gem} , 10.4, 8'A-H), 3.34 (2.1H, s, OCH₃), 3.37* (0.9H, s, OCH₃), 3.70–3.85 (1H, m, 4'-H), 4.21 (2H, br s, OCH₂), 5.42 (0.7H, d, J_{5',4'} 1.9, 5'-H), 5.50* (0.3H, d, J_{5'.4'} 3.9, 5'-H), 5.73 (2H, brs, NH₂), 6.60–6.68 (2H, m, 3-H and 5-H), 7.26 (1H, td, J7.4, 1.9, 4-H) and 7.84 (1H, dd, J1.4, 8.1, 6-H); $\delta_{\rm C}$ (50 MHz, CDCl₃) 12.5 (CH₃, NCH₂CH₃), 21.0 (CH₂, C-12'), 24.3 (CH₂, C-2'), 32.3 (CH₂, C-11'), 36.4 (CH₂, C-3'), 36.5 (quat., C-1'), 39.2 (CH₂, C-13'), 40.7 (quat., C-7'), 52.0 (CH₂, NCH₂CH₃), 55.7 (CH₃, OCH₃), 55.8* (CH₃, OCH₃), 62.8 (CH₂, C-10'), 67.3 (CH₂, C-8'), 67.7 (CH₂, OCH₂), 74.4* (CH, C-4'), 76.0 (CH, C-4'), 110.2 (quat., C-1), 115.3* (CH, C-5'), 116.2 (CH, C-5'), 116.4 (CH, C-3), 116.6 (CH, C-5), 131.1 (CH, C-6), 134.0 (CH, C-4), 149.3 (quat., C-6'), 150.5 (quat., C-2) and 166.9 (quat., OC=O); m/z (EI) 384 $(M^+, 37\%)$, 369 $(M - CH_3, 29)$, 353 $(M - OCH_3, 27)$, 264 (M $NH_2C_6H_4CO$, 56), 248 (M - $NH_2C_6H_4CO_2$, 57), 120 $(C_7H_6NO, 69)$ and 72 (100). Found M⁺, 384.2419. $C_{23}H_{32}N_2O_3$ requires M^+ , 384.2413.

$(1''R^*,7''S^*,3'R^*)$ - and $(1''R^*,7''S^*,3'S^*)$ -(9-Ethyl-4-methoxy-9-aza-tricyclo $[5.3.3.0^{1.6}]$ tridec-5-en-7-yl)methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate 18

Anthranilate ester 17 (72 mg, 0.187 mmol) and 2-methyl-succinic anhydride (64 mg, 0.561 mmol) were heated together at 125 °C for 36 h. After this time the crude mixture was dissolved in warm ethyl acetate (10 mL), washed with sat. sodium

bicarbonate solution (30 mL) and brine (30 mL) then dried (MgSO₄) and concentrated in vacuo. The crude product was purified by flash chromatography using 3: 2 hexane-ethyl acetate as eluent to afford the title compound 18 (45 mg, 50%) as a yellow oil and as a mixture of isomers. $v_{\text{max}}(\text{NaCl})/\text{cm}^{-1}$ 2931 (C-H), 1781 (N-C=O), 1716 (C=O), 1602, 1493, 1454, 1391, 1259 and 1186; $\delta_{\rm H}$ (200 MHz, CDCl₃) 1.03 (3H, t, J 7.1, NCH₂CH₃), 1.20–1.35 (2H, m, 11"B-H and 12"B-H), 1.35–1.74 (9H, m, 3'-CH₃, 2"-CH₂, 3"-CH₂, 11"A-H and 13"-H), 1.79 (1H, d, J_{gem} 11.2, 10"B-H), 1.96 (2H, q, J 7.2, NCH₂CH₃), 2.13–2.29 (2H, m, 10"A-H and 13"A-H), 2.45-2.68 (1H, m, 3'-H), 2.79 (1H, d, J_{gem} 10.3, 8"B-H), 2.83-3.09 (4H, br m, 4'-CH₂, 8"A-H and 12"A-H), 3.33 (2.1H, s, OCH₃), 3.36* (0.9H, s, OCH₃), 3.68-3.81 (1H, m, 4"-H), 4.12 (2H, br s, OCH₂), 5.36 (0.7H, d, $J_{5'',4''}$ 2.0, 5"-H), 5.43* (0.3H, d, $J_{5'',4''}$ 3.9, 5"-H), 7.24 (1H, dd, J 1.1, 7.7, 3-H), 7.51 (1H, td, J7.8, 1.4, 5-H), 7.65 (1H, td, J7.7, 1.7, 4-H) and 8.08 (1H, dd, J 1.6, 7.8, 6-H); $\delta_{\rm C}$ (50 MHz, CDCl₃) 12.5 (CH₃, NCH₂CH₃), 16.3 (CH₃, 3'-CH₃), 20.9 (CH₂, C-12"), 24.3 (CH₂, C-2"), 32.2 (CH₂, C-11"), 35.2 (CH, C-3'), 36.2 (quat., C-1"), 36.5 (quat., C-3"), 36.9 (CH₂, C-4'), 39.1 (CH₂, C-13"), 40.7 (quat., C-7"), 52.0 (CH₂, NCH₂CH₃), 55.7 (CH₃, OCH₃), 55.9* (CH₃, OCH₃), 62.6 (CH₂, C-10"), 67.2 (CH₂, C-8"), 70.5 (CH₂, OCH₂), 74.3* (CH, C-4"), 75.9 (CH, C-4"), 115.4* (CH, C-5"), 116.5 (CH, C-5"), 127.2 (quat., C-1), 129.3 (CH, C-5), 129.8 (CH, C-3), 131.4 (CH, C-6), 132.8 (quat., C-2), 133.3 (CH, C-4), 147.0 (quat., C-6"), 148.5* (quat., C-6"), 164.2 (quat., OC=O), 175.8 (quat., C-5') and 179.9 (quat., C-2'); *m*/*z* (EI) 480 (M⁺, 26%), 449 (M – OCH₃, 26), 264 $(M - C_{12}H_{10}O_3N, 67)$, 248 $(M - C_{12}H_{10}O_4N, 61)$ and 72 (100). Found M⁺, 480.2619. C₂₈H₃₆N₂O₅ requires M⁺, 480.2624.

References

- 1 R. H. Manske, Can. J. Res., Sect B, 1938, 16, 57.
- 2 S. W. Pelletier, N. V. Mody, B. S. Joshi and L. C. Schramm, in *Alkaloids: Chemical and Biological Perspectives*, ed. S. W. Pelletier, J. Wiley and Sons, New York, 1984, vol. 2, p. 205.
- 3 S. W. Pelletier and B. S. Joshi, in *Alkaloids: Chemical and Biological Perspectives*, ed. S. W. Pelletier, Springer-Verlag, New York, 1991, vol. 7, p. 297.
- 4 K. R. Jennings, D. G. Brown and D. P. Wright, *Experientia*, 1986, **42**, 611.
- 5 S. Wonnacott, E. X. Albuquerque and D. Bertrand, *Methods in Neurosciences*, 1993, 12, 263; L. P. Dwoskin and P. A. Crooks, *J. Pharmacol. Exp. Ther.*, 2001, 298, 395.
- 6 J. A. Goodson, J. Chem. Soc., 1943, 139.
- 7 D. J. Hardick, I. S. Blagbrough, G. Cooper, B. V. L. Potter, T. Critchley and S. Wonnacott, J. Med. Chem., 1996, 39, 4860.
- P. A. Coates, I. S. Blagbrough, D. J. Hardick, M. G. Rowan,
 S. Wonnacott and B. V. Potter, *Tetrahedron Lett.*, 1994, 35, 8701; I.
 S. Blagbrough, P. A. Coates, D. J. Hardick, T. Lewis, M. G. Rowan,
 S. Wonnacott and B. V. L. Potter, *Tetrahedron Lett.*, 1994, 35, 8705;
 D. J. Hardick, I. S. Blagbrough, S. Wonnacott and B. V. Potter, *Tetrahedron Lett.*, 1994, 35, 3371; I. S. Blagbrough, D. J. Hardick,
 S. Wonnacott and B. V. Potter, *Tetrahedron Lett.*, 1994, 35, 3367.
- 9 J. M. Jacyno, J. S. Harwood, N. Lin, J. E. Campbell, J. P. Sullivan and M. W. Holladay, *J. Nat. Prod.*, 1996, **59**, 707; H. A. Navarro, D. Zhong, P. Abraham, H. Xu and F. I. Carroll, *J. Med. Chem.*, 2000, **43**, 142.
- 10 S. C. Bergmeier, D. J. Lapinsky, R. B. Free and D. B. McKay, *Bioorg. Med. Chem. Lett.*, 1999, 9, 2263.
- 11 P. A. Coates, I. S. Blagbrough, M. G. Rowan, B. V. L. Potter, D. P. J. Pearson and T. Lewis, *Tetrahedron Lett.*, 1994, 35, 8709; P. A. Coates, I. S. Blagbrough, M. G. Rowan, D. P. J. Pearson, T. Lewis and B. V. L. Potter, *J. Pharm. Pharmacol.*, 1996, 48, 210.
- G. Grangier, W. J. Trigg, T. Lewis, M. G. Rowan, B. V. L. Potter and I. S. Blagbrough, *Tetrahedron Lett.*, 1998, 39, 889; W. J. Trigg, G. Grangier, T. Lewis, M. G. Rowan, B. V. L. Potter and I. S. Blagbrough, *Tetrahedron Lett.*, 1998, 39, 893.
- 13 G. A. Kraus and E. Dneprovskaia, Tetrahedron Lett., 1998, 39, 2451.
- 14 L. C. Baillie, J. R. Bearder and D. A. Whiting, J. Chem. Soc., Chem. Commun., 1994, 2487; L. C. Baillie, J. R. Bearder, J. A. Sherringham and D. A. Whiting, J. Chem. Soc., Perkin Trans. 1, 1997, 2687; L. C. Baillie, J. R. Bearder, J. A. Sherringham and D. A. Whiting, J. Chem. Soc., Perkin Trans. 1, 1998, 4047; L. C. Baillie, A. Batsanov, J. R.

- Bearder and D. A. Whiting, J. Chem. Soc., Perkin Trans. 1, 1998, 3471
- 15 A. R. L. Davies, D. J. Hardick, I. S. Blagborough, B. V. Potter, A. J. Wolstenholme and S. Wonnacott, *Biochem. Soc. Trans.*, 1997, 25, 5458.
- 16 S. N. Huckin and L. J. Weiler, J. Am. Chem. Soc., 1974, 96, 1082.
- 17 S. A. Kates, M. A. Dombroski and B. B. Snider, J. Org. Chem., 1991, 55, 2427.
- 18 G. A. Kraus and S. Jianmin, J. Org. Chem., 1990, 55, 5424; M. Ihara, M. Suzuki, K. Fukumoto and C. Kabuto, J. Am. Chem. Soc., 1990, 112, 1164.
- 19 M. S. Arias-Perez, A. Alejo, E. Galvaz, S. M. Perez and M. J. Santos, J. Mol. Struct., 1995, 349, 159.
- 20 G. W. Kalbalka, S. Yu and N. Li, *Tetrahedron Lett.*, 1997, 38, 5455.
- 21 T. Tsuji, Synthesis, 1984, 369.
- 22 T. Tsuji, I. Shimizu and K. Yamamoto, *Tetrahedron Lett.*, 1976, 34, 2975
- 23 F. J. McQuillin and D. G. Parker, *J. Chem. Soc., Perkin Trans.* 1, 1974, 809.
- 24 J. Poirier and L. Hennequin, Tetrahedron, 1989, 45, 4191.
- 25 R. P. Staiger and E. B. Miller, J. Org. Chem., 1959, 24, 1214; M. C. Venuti, Synthesis, 1982, 266.
- 26 D. Barker, M. D. McLeod, M. A. Brimble and G. P. Savage, Tetrahedron Lett., 2001, 42, 1785.
- 27 A. Schepartz and R. Breslow, J. Am. Chem. Soc., 1987, 109, 1814.